A trio of distinguished experts interviewed by GEN, and two investment firms that track biopharma stocks, agreed that three of the four candidates showed sufficient promise in Phase I or Phase I/II studies to warrant interest from researchers, industry observers, and others in upcoming trials
SCG says it has developed in-house cGMP manufacturing capabilities to supply high-quality cell therapy products to patients.
And there are benefits of plant cell expression systems, notably their impact on the cost of goods sold (COGS).
A British-based cell therapy company is using smart operations to streamline its viral vector processing.
CMS proposed Medicare’s CGT reimbursement policy matches Medicaid’s sickle cell disease policy, forming a unified government approach.
Prodigiosin applications extend from manufacturing pigment and environmental-control agent to antibiotic and potential oncology drug.
Insilico Medicine is heading to the clinic with a treatment for methylthioadenosine phosphorylase (MTAP) deleted cancers.
New data-intensive platforms continue to leverage artificial intelligence tools for improved speed and failure rate reductions for drug discovery.
The mini colons replicate both the physical structure and cellular diversity in the colon in both healthy and diseased states.
Regeneron Pharmaceuticals will use Mammoth Biosciences’ CRISPR-based ultracompact gene editing platform to develop in vivo therapies for tissues and cell types beyond the liver.
Workflow design and data management are pivotal components of cell and gene therapy research and development. Advances in artificial intelligence, informatics, and automation have made…
